Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented new preclinical data from its immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The data, featured in one oral and two poster sessions, highlighted the potential of two candidates: TNX-1700 and TNX-4700. These findings underscore Tonix's expanding efforts in oncology, complementing its established focus on central nervous system (CNS) and immunology treatments.
TNX-1700, a monoclonal antibody targeting a novel immune checkpoint, demonstrated potential in reducing inflammation and tumor progression in preclinical models of gastric cancer. The data also showed favorable pharmacokinetics, suggesting the candidate could be a viable therapeutic option. Gastric cancer remains a significant unmet medical need, with limited treatment options for advanced stages. TNX-1700's mechanism aims to modulate the tumor microenvironment, potentially improving outcomes for patients.
TNX-4700, another candidate from the immuno-oncology pipeline, targets BTLA (B- and T-lymphocyte attenuator), a checkpoint receptor that suppresses immune responses. Preclinical in vitro activity showed TNX-4700's ability to enhance T-cell activation, indicating its potential as a monotherapy or in combination with other checkpoint inhibitors like anti-PD-1. The combination approach is a growing trend in cancer immunotherapy, aiming to overcome resistance and improve response rates.
Tonix Pharmaceuticals is a fully integrated commercial-stage biotechnology company, best known for its recently approved fibromyalgia treatment TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg). The company's CNS commercial infrastructure supports marketed products for acute migraine, including Zembrace SymTouch and Tosymra. Beyond CNS, Tonix is advancing a pipeline of immunology programs, such as TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection.
The presentation at AACR 2026 marks a strategic step for Tonix in oncology, a field with high unmet need and commercial potential. While these are preclinical data, they provide a foundation for further development. Investors can find the latest updates on TNXP in the company's newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/Oly6o.
Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. The AACR data provide early evidence of potential but require further validation in clinical trials.
